![Large study indicates no benefit from colchicine on COVID-19 mortality - Hospital Pharmacy EuropeHospital Pharmacy Europe Large study indicates no benefit from colchicine on COVID-19 mortality - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2021/05/HPE-GettyImages-952083974.jpg)
Large study indicates no benefit from colchicine on COVID-19 mortality - Hospital Pharmacy EuropeHospital Pharmacy Europe
![A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests - Medical Update Online A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests - Medical Update Online](https://medicalupdateonline.com/wp-content/uploads/2023/05/AdobeStock_599376457.jpg)
A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests - Medical Update Online
![A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests | UCLA Health A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests | UCLA Health](https://www.uclahealth.org/sites/default/files/styles/landscape_3x2_016000_640x427/public/images/b4/box-colchicine-wikimedia-commons-700x466.jpg?f=010bbdc8&itok=iMwPq4XF)
A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests | UCLA Health
![Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial - The Lancet Respiratory Medicine Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/85629e38-dda1-4c05-afc4-5609b9409813/gr1.gif)
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial - The Lancet Respiratory Medicine
![Antibiotic Steward Bassam Ghanem🆔🌟 on X: "Important NIH 💥💥 Before prescribing ritonavir-boosted nirmatrelvir (Paxlovid), clinicians should carefully review concomitant medications, including over-the-counter medicines and herbal supplements, to ... Antibiotic Steward Bassam Ghanem🆔🌟 on X: "Important NIH 💥💥 Before prescribing ritonavir-boosted nirmatrelvir (Paxlovid), clinicians should carefully review concomitant medications, including over-the-counter medicines and herbal supplements, to ...](https://pbs.twimg.com/media/FH6AXKtWUAwKLdQ.jpg:large)
Antibiotic Steward Bassam Ghanem🆔🌟 on X: "Important NIH 💥💥 Before prescribing ritonavir-boosted nirmatrelvir (Paxlovid), clinicians should carefully review concomitant medications, including over-the-counter medicines and herbal supplements, to ...
![Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial - The Lancet Rheumatology Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial - The Lancet Rheumatology](https://www.thelancet.com/cms/asset/a052f7cb-094a-4623-b9ee-99d0c5894ee3/gr1.jpg)